Additionally, we focused on investigating FDX1 as the primary subject of our investigation, examining its expression, prognosis, tumor immune microenvironment, substance metabolism pathway, immune cell infiltration, immunotherapy and chemotherapy drug sensitivity in GBM. The gene discussed is FDX1; the disease is glioblastoma.